QSAM Biosciences, Inc. (QSAM)
OTCMKTS: QSAM · Delayed Price · USD
7.40
0.00 (0.00%)
Apr 17, 2024, 2:44 PM EDT - Market closed
Company Description
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases.
The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical.
It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020.
The company was incorporated in 2004 and is headquartered in Austin, Texas.
QSAM Biosciences, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Douglas R. Baum |
Contact Details
Address: 9442 Capital Of Texas Hwy N, Plaza 1, Suite 500 Austin, Texas 78759 United States | |
| Phone | 512-343-4558 |
| Website | qsambio.com |
Stock Details
| Ticker Symbol | QSAM |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001310527 |
| CUSIP Number | 74738N103 |
| ISIN Number | US74738N2027 |
| Employer ID | 20-1602779 |
| SIC Code | 2842 |
Key Executives
| Name | Position |
|---|---|
| Dr. C. Richard Piazza MA, Ph.D. | Co-Founder and Executive Chairman |
| Douglas R. Baum | Co-Founder, Chief Executive Officer and Director |
| Christopher M. Nelson | General Counsel and Executive Vice President of Business Development |
| Adam King CPA | Chief Financial Officer |
| Namrata Chand | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | DEFM14C | Filing |
| Apr 1, 2024 | PREM14C | Filing |
| Mar 20, 2024 | 10-K | Annual Report |
| Feb 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | 8-K | Current Report |
| Jan 16, 2024 | 8-K | Current Report |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |